- Home
- BCOW vs IMMX Comparison
BCOW vs IMMX Comparison
Compare BCOW & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCOW
- IMMX
- Stock Information
- Founded
- BCOW 1895
- IMMX 2014
- Country
- BCOW United States
- IMMX United States
- Employees
- BCOW N/A
- IMMX N/A
- Industry
- BCOW Finance: Consumer Services
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- BCOW Finance
- IMMX Health Care
- Exchange
- BCOW Nasdaq
- IMMX Nasdaq
- Market Cap
- BCOW 55.6M
- IMMX 55.3M
- IPO Year
- BCOW 2019
- IMMX 2021
- Fundamental
- Price
- BCOW $10.02
- IMMX $1.76
- Analyst Decision
- BCOW
- IMMX Strong Buy
- Analyst Count
- BCOW 0
- IMMX 1
- Target Price
- BCOW N/A
- IMMX $7.00
- AVG Volume (30 Days)
- BCOW 13.1K
- IMMX 83.5K
- Earning Date
- BCOW 03-28-2025
- IMMX 03-28-2025
- Dividend Yield
- BCOW N/A
- IMMX N/A
- EPS Growth
- BCOW N/A
- IMMX N/A
- EPS
- BCOW N/A
- IMMX N/A
- Revenue
- BCOW $11,828,000.00
- IMMX N/A
- Revenue This Year
- BCOW N/A
- IMMX N/A
- Revenue Next Year
- BCOW N/A
- IMMX $600.00
- P/E Ratio
- BCOW N/A
- IMMX N/A
- Revenue Growth
- BCOW N/A
- IMMX N/A
- 52 Week Low
- BCOW $6.69
- IMMX $1.26
- 52 Week High
- BCOW $10.69
- IMMX $3.80
- Technical
- Relative Strength Index (RSI)
- BCOW 53.78
- IMMX 31.71
- Support Level
- BCOW $9.58
- IMMX $1.85
- Resistance Level
- BCOW $10.45
- IMMX $2.14
- Average True Range (ATR)
- BCOW 0.24
- IMMX 0.12
- MACD
- BCOW 0.03
- IMMX -0.02
- Stochastic Oscillator
- BCOW 60.19
- IMMX 8.43
About BCOW 1895 Bancorp of Wisconsin Inc. (MD)
1895 Bancorp of Wisconsin Inc acts as the mutual holding company reorganization of PyraMax Bank, FSB, to become the savings and loan holding company of PyraMax Bank, FSB. Its business consists predominantly of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one-to-four family residential real estate loans, commercial real estate loans, commercial loans, and consumer loans.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.